Home  > News  > Noteworthy

Noteworthy

Please find below news in brief from Ascenion, its partners and the technology transfer sector:

02.05.2019

12th BioVaria on May 8 - 9, 2019 – Don’t miss the opportunity!

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Top-tier academic institutions and universities from all over Europe will present over 60 attractive partnering and investment opportunities in the life-science field.

  • Unparalleled density of highly innovative commercial opportunities
  • 15 technology transfer partners from five European countries
  • 10 life-science startups from Austria, Czech Republic, Denmark, Germany and Norway participating in this year’s Startup Pitch and Partner event
  • Interactive panel discussion on “From stem cells to therapy: Development of cell based approaches in regenerative medicine” moderated by Dr Martin Raditsch, CEO, Innovectis GmbH.

Register here www.biovaria.org.

Further information:

Technologies online

Startups

30.04.2019

OMEICOS starts Phase II Trial in Atrial Fibrillation

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled, double-blind, randomized PROMISE-AF study will evaluate the efficacy and safety of the candidate in patients with persistent atrial fibrillation (AF). In total, the company expects to enrol up to 120 participants in four European countries.

OMT-28, a synthetic small molecule analogue of a natural omega-3 fatty acid metabolite, targets one of nature’s most important cell-protective pathways. If successful, it would introduce a novel treatment modality in the segment of anti-arrhythmic drugs, with potential benefits for millions of patients.

For further information see OMEICOS’ press release


29.04.2019

Charité BIH Entrepreneurship Summit, Berlin, June 17 - 18, 2019

Join over 400 experts in medical innovation to discuss global challenges and pioneering technologies in healthcare. During two conference days, you will get access to entrepreneurs, scientists and clinicians, policymakers, investors, and industry leaders.

The agenda features influential speakers from Germany, Europe, Israel, the United States, and Australia. The keynote topics of 2019 will include AI in healthcare, drug repurposing, investment models, digital therapeutics, and clinical trials. This year has a special focus on the Massachusetts region and therefore has a strong emphasis on transatlantic collaboration.

The Life Sciences Venture Market offers opportunities for entrepreneurs to present their companies to international investors. In addition, the following interactive workshops on relevant strategic issues are offered:

  • Lessons learned from the fundraising trenches: the good, the bad and the ugly
    Charlie Cameron, Cooley LLP Boston, MA and John Hession, Morse Barnes-Brown Pendleton, Waltham, MA
  • Understanding Healthcare and Hospitals – what innovators and founders need to know to success in the world of rules and regulation in Germany. A perspective from consulting experts. Christian Wallwiener and Marina Leonie Moskvina, WMC Healthcare Munich, Germany


Ascenion is partner of the Charité BIH Entrepreneurship Summit 2019. As a member of our network you save up to 33% at registration. Contact us!

Find out more about the Summit and register at: www.charite-summit.de.

23.04.2019

Ascenion supports collaboration agreement between HZI / HIPS and GARDP

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with the Global Antibiotic Research and Development Partnership (GARDP) to discover novel antibiotics. Ascenion, the HZI’s technology transfer partner, supported the deal.

The partners will focus on drug-resistant pathogens that are most threatening to public health according to WHO’s classification. HIPS will contribute its unique library of natural compounds to the global drug discovery initiative, which brings together leading institutes and public private partnerships to combat antibacterial resistance. Besides HIPS and GARDP, it embraces the open-access screening initiative CO-ADD and Calibr, the translational division of Scripps Research.

For further information see the HZI's press release

08.04.2019

Gramibactin is Leibniz Compound of the Year 2019

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the iron supply of both the microorganisms and their host plants. It captures iron(III) from the environment through N nitroso-hydroxylamine groups that have not been observed in any other natural iron transporter so far. This unique binding motif not only fixes iron with high affinity but also serves as a nitric oxide (NO) donor.

These findings may contribute to improving plant growth and crop yield in a natural way. In plants, iron is essential for chlorophyll production, and NO is involved in several regulatory processes. Gramibactin was discovered by Christian Hertweck and his team at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI).

Due to the strong potential it holds for cereal production, it was named ‘Leibniz Compound of the Year’. The compound is available for licencing or co-development through Ascenion, the HKI’s technology transfer partner.

Further information:

07.04.2019

ISAR Bioscience Translational R&D project competition: Call for proposals

ISAR Bioscience is sponsor of BioVaria 2019, Europe’s leading showcasing event for life science technologies. ISAR is committed to translational R&D in the field of applied stem cell and regenerative medicine research. ISAR invites scientists and R&D organizations to submit early-stage or more advanced translational R&D project proposals for recognition, support & funding. All areas of applied biomedical and therapeutic research are welcome but R&D project proposals must encompass ISAR key technologies such as for instance hiPSC and cell differentiation, genome engineering, next generation disease models for therapeutic discovery and regenerative medicine, cell-based models for industrial biotechnology applications, 3D spheroid/organoid tissue models, microfluidics, or laboratory automation. Confidentiality is guaranteed and all proposals will be internally evaluated. Select applicants will be invited to pitch their translational R&D project to the ISAR jury in a confidential ISAR satellite session at BioVaria 2019. The winning ISAR R&D proposal will be announced and honored with € 2,000 at the ISAR award ceremony held at BioVaria 2019 and will be further evaluated whether it is eligible for ISAR support and funding. R&D project proposals must be submitted no later than April 12th 2019.

Further information and application instructions see competition website.

06.04.2019

Join ASTP-Proton’s 20th Annual Conference on 21 – 23 May 2019 in Dublin

Get ready for Europe’s largest event for knowledge and technology transfer (KTT): ASTP-Proton’s Annual Conference is taking place in Dublin on 21 – 23 May 2019. The meeting attracts hundreds of KTT professionals from across the world as well as major stakeholders from industry, SMEs, finance and government. Two interactive days offer multiple opportunities for learning and networking. The program includes inspiring key notes from international top speakers, e.g. from Israel and Saudi Arabia, and workshops and panel discussions on hot topics such as artificial intelligence. In addition, participants can arrange for one-on-one meetings with representatives from EU projects, KTT-offices or industry to share experience and identify opportunities for collaboration.

Arrive on 21 May in the morning and join the pre-conference program which includes two free training workshops, a visit to the Guinness Enterprise Centre, and walking tour of Dublin!

For further information on programme and registration please visit the conference website.

04.04.2019

EIT Health Accelerator: Dedicated support for Europe’s top entrepreneurs

This is an exciting opportunity for European healthcare entrepreneurs, start-ups and SMEs: EIT Health invites you to apply for participation in the EIT Health Accelerator, a EU-backed programme providing dedicated support at every stage of the business development process, from ideation to scale-up. Supportive actions break down into three key sections: INCUBATE, VALIDATE and SCALE. Choose the programme that best suits your venture’s development stage:

  • INCUBATE targets academics working on ideas in medtech, biotech or digital health. It offers access to dedicated Bootcamp programmes, which are designed to help start-ups develop and validate their business idea, and prepare to launch across the European market.
  • VALIDATE is for start-ups and SMEs that want to test and improve their products. It includes access to test labs, mentoring, funding and training, e.g. in the fields of regulatory and marketing. 
  • SCALE focuses on more mature start-ups and SMEs. It provides access to advanced tools and networks for financing and market expansion.


Don’t miss the opportunity to benefit from the EU’s vibrant start-up ecosystem.

  • Learn more about the EIT Accelerator.
  • If you are located in the DACH region also explore the slack group for start-ups where information about upcoming deadlines and opportunities is published regularly.

12.03.2019

Ascenion supports negotiations for licence agreement between HZI and InvivoGen

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence agreement between the institute and InvivoGen, a global provider of life-science research products. Under the terms of the agreement the company obtains the right to commercialise c-di-AMP as a vaccine adjuvant for research projects. The compound is a second messenger in bacteria, where it plays a crucial role in the coordination of growth and the establishment of bacterial infection. HZI researchers have shown that it can boost cellular immune response when co-administered with vaccines via various routes, including mucosal applications. This makes it an attractive adjuvant for all approaches aiming to establish effective immune protection, involving the mucosa as point of entrance.

The compound is available at preclinical grade from InvivoGen at 
www.invivogen.com/cdiamp-vaccigrade.

22.02.2019

HZI and Evotec to collaborate for novel antibiotics

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a collaboration agreement between the institute and Evotec. The partners will combine their platforms and expertise to develop antibiotics against resistant pathogens that pose an increasing threat to public health. They will first focus on cystobactamids, a promising group of natural antibiotic agents active against the most dangerous gram-negative bacteria on the WHO priority list.

The project will benefit from the partners’ complementary technology and know-how. The HZI provides access to its unique collection of natural products and in-vitro and in-vivo models of bacterial infection, while Evotec contributes its leading drug discovery platform, medicinal chemistry and pharmacology expertise and its world-leading collection of bacterial pathogens. The collaboration will initially run for three years.

Further information: See press release
 

20.02.2019

In cooperation with TechnologieAllianz: Ascenion offers training courses

TechnologieAllianz is the German association for knowledge and technology transfer (KTT) and brings together universities, national research institutions and transfer service providers in a nationwide network. TechnologieAllianz is promoting the development and recognition of the KTT profession in Germany and is also striving towards sharing best practice among their members as well as with other international KTT institutions and networks worldwide. Additionally, TechnologieAllianz organises KTT training, workshops and conferences.

As a member of TechnologieAllianz, Ascenion will conduct a further-education training course on the topic of equity management. 

Learn more.

19.02.2019

Welcome to the team!

End of last year, Dr Claus Schulte joined Ascenion’s team in Munich as Project and Start-up Manager. He draws on many years’ experience in the life-sciences industry, in technology transfer and the start-up scene. He led various business development and licensing departments and gained experience in founding and managing start-up companies.

Claus holds a degree in biology from Münster University and a PhD in Neurodevelopmental Biology from Cambridge University, UK.

18.02.2019

Behind the scenes of technology transfer

At the end of January, 19 technology transfer specialists representing Ascenion’s partner institutions in Germany and Austria gathered in Munich for the company’s dedicated TT-workshop. The workshop represents a unique platform for Ascenion’s partners to share experiences from the various research organizations and expand their TT-know-how in a cooperative und trusting atmosphere. This year’s key topics were artificial intelligence in medicine, patenting of computer-implemented inventions as well as participation of academic research organizations in start-ups and the structuring of related agreements. These were presented by experts from Ascenion and external speakers including an IP-expert from the European Patent Office, a data scientist from the Fraunhofer Institute for Intelligent Analysis and Information Systems (IAIS) and a Strategic Alliance Manager from the German Cancer Research Center (DKFZ) who provided intriguing insights into the institute’s industry collaborations. Participants went home inspired with lots of valuable information and new contacts and an eagerness for next year’s workshop.

12.02.2019

Early bird deadline for TechnologieAllianz’ Annual Meeting has been extended to February 15, 2019

This year’s Annual Meeting of TechnologieAllianz, Germany’s association for knowledge and technology transfer (KTT) will take place on 20-21 March 2019 in Frankfurt, Germany. For the first time, it has been extended to two days providing extra dedicated time for international networking and program highlights.

  • Gain valuable insights from keynotes, workshops and panel discussions presented by leading experts from across Europe and the US.
  • Learn about key trends and topics in the field including the development of the European KTT landscape, measuring and evaluating KTT, funding tools, industry cooperation, open innovation, transfer of IT, and innovative licensing models.
  • Share experience and network with leaders in KTT from academia and industry.
  • Shape the future of KTT.

Secure your early bird ticket here.

28.01.2019

Save the date: Next BioVaria on 8-9 May 2019 in Munich

BioVaria is organised by Ascenion and several other technology transfer organisations from all across Europe. The conference brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Top-tier academic institutions and universities from all over Europe will present over 60 attractive partnering and investment opportunities in the life-science field – each one selected for BioVaria in a peer-review process.

Selected pre- and post-seed startups from all life-science areas (pharma, diagnostics, medtech, digital health) will have the chance to pitch their companies during the two-day Startup Pitch & Partner program. During one-to-one Speed Dating, they will have the opportunity to connect directly with potential investors and receive individual advice from industry experts in the dedicated mentoring sessions. Application deadline is March 1, 2019 - secure your place!

BioVaria offers a unique opportunity to learn about many exceptionally attractive and innovative projects and discuss them directly with the scientists during two days.

Don’t miss BioVaria 2019 if you are a scout, business developer or investor! Register now!

Apply here for the Startup Pitch & Partner program!